| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgical Wound Infection | 30 | 2022 | 168 | 7.730 |
Why?
|
| Telemedicine | 14 | 2022 | 699 | 3.350 |
Why?
|
| Epidemiological Monitoring | 6 | 2019 | 23 | 2.660 |
Why?
|
| Cross Infection | 17 | 2020 | 195 | 2.560 |
Why?
|
| Patient Generated Health Data | 8 | 2019 | 10 | 2.490 |
Why?
|
| Pneumonia, Ventilator-Associated | 9 | 2014 | 31 | 2.490 |
Why?
|
| Appendicitis | 10 | 2022 | 55 | 2.380 |
Why?
|
| Wounds and Injuries | 9 | 2012 | 334 | 2.040 |
Why?
|
| Anti-Bacterial Agents | 26 | 2022 | 1026 | 1.860 |
Why?
|
| Mobile Applications | 5 | 2022 | 138 | 1.440 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2019 | 51 | 1.380 |
Why?
|
| Patient Discharge | 6 | 2017 | 294 | 1.350 |
Why?
|
| Infection Control | 5 | 2020 | 101 | 1.220 |
Why?
|
| Appendectomy | 9 | 2022 | 47 | 1.170 |
Why?
|
| Bacterial Infections | 9 | 2010 | 163 | 0.990 |
Why?
|
| Humans | 95 | 2023 | 68525 | 0.990 |
Why?
|
| Surgical Wound | 2 | 2022 | 8 | 0.980 |
Why?
|
| Photography | 4 | 2019 | 37 | 0.920 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 143 | 0.900 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 154 | 0.900 |
Why?
|
| Postoperative Period | 4 | 2019 | 238 | 0.890 |
Why?
|
| Workflow | 2 | 2022 | 100 | 0.870 |
Why?
|
| Surgical Procedures, Operative | 4 | 2021 | 124 | 0.860 |
Why?
|
| Health Services Research | 3 | 2019 | 209 | 0.860 |
Why?
|
| Pandemics | 3 | 2020 | 346 | 0.860 |
Why?
|
| Antimicrobial Stewardship | 1 | 2021 | 33 | 0.800 |
Why?
|
| Patient Participation | 2 | 2019 | 145 | 0.800 |
Why?
|
| Personal Protective Equipment | 2 | 2020 | 27 | 0.790 |
Why?
|
| Smartphone | 1 | 2021 | 69 | 0.740 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 114 | 0.720 |
Why?
|
| Drug Resistance, Bacterial | 5 | 2009 | 98 | 0.720 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2018 | 30 | 0.720 |
Why?
|
| Clinical Protocols | 1 | 2020 | 172 | 0.710 |
Why?
|
| Health Information Systems | 1 | 2019 | 18 | 0.700 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 581 | 0.700 |
Why?
|
| Operating Rooms | 1 | 2020 | 108 | 0.690 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 445 | 0.680 |
Why?
|
| Disease Management | 2 | 2019 | 248 | 0.650 |
Why?
|
| Fasciitis, Necrotizing | 2 | 2017 | 15 | 0.640 |
Why?
|
| Information Dissemination | 1 | 2019 | 113 | 0.640 |
Why?
|
| Adult | 38 | 2022 | 21375 | 0.630 |
Why?
|
| Critical Care | 4 | 2020 | 263 | 0.600 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 191 | 0.600 |
Why?
|
| Pneumonia | 2 | 2014 | 110 | 0.580 |
Why?
|
| Soft Tissue Infections | 2 | 2014 | 19 | 0.580 |
Why?
|
| Intraabdominal Infections | 4 | 2017 | 19 | 0.570 |
Why?
|
| Risk Factors | 18 | 2017 | 5719 | 0.550 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2019 | 689 | 0.540 |
Why?
|
| Postoperative Care | 1 | 2016 | 163 | 0.540 |
Why?
|
| Middle Aged | 42 | 2020 | 21119 | 0.540 |
Why?
|
| Hospital Mortality | 10 | 2017 | 384 | 0.530 |
Why?
|
| Patient Compliance | 2 | 2017 | 402 | 0.510 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 89 | 0.510 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2019 | 47 | 0.510 |
Why?
|
| Video Recording | 1 | 2015 | 145 | 0.510 |
Why?
|
| Respiratory Aspiration | 1 | 2014 | 13 | 0.500 |
Why?
|
| Clinical Competence | 2 | 2019 | 657 | 0.490 |
Why?
|
| Female | 47 | 2022 | 38015 | 0.490 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 115 | 0.490 |
Why?
|
| Male | 46 | 2022 | 37281 | 0.490 |
Why?
|
| Gram-Negative Bacterial Infections | 4 | 2008 | 62 | 0.490 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2013 | 40 | 0.480 |
Why?
|
| Critical Illness | 6 | 2014 | 191 | 0.470 |
Why?
|
| Prospective Studies | 19 | 2019 | 3702 | 0.470 |
Why?
|
| Retrospective Studies | 19 | 2022 | 7264 | 0.450 |
Why?
|
| Aircraft | 1 | 2011 | 30 | 0.420 |
Why?
|
| Intubation | 1 | 2011 | 20 | 0.410 |
Why?
|
| Intubation, Intratracheal | 2 | 2020 | 99 | 0.410 |
Why?
|
| Survivors | 1 | 2014 | 254 | 0.410 |
Why?
|
| Appendix | 2 | 2022 | 9 | 0.410 |
Why?
|
| Chlorhexidine | 2 | 2013 | 12 | 0.400 |
Why?
|
| Anti-Infective Agents | 3 | 2022 | 166 | 0.400 |
Why?
|
| Patient Transfer | 2 | 2011 | 86 | 0.400 |
Why?
|
| Drug Administration Schedule | 10 | 2016 | 567 | 0.390 |
Why?
|
| Triage | 1 | 2011 | 109 | 0.380 |
Why?
|
| Baths | 1 | 2010 | 3 | 0.370 |
Why?
|
| Intensive Care Units | 11 | 2014 | 344 | 0.370 |
Why?
|
| Sepsis | 3 | 2019 | 233 | 0.360 |
Why?
|
| Bacteremia | 1 | 2012 | 155 | 0.360 |
Why?
|
| Treatment Outcome | 16 | 2022 | 7028 | 0.350 |
Why?
|
| Myocardium | 2 | 2007 | 1204 | 0.340 |
Why?
|
| Terminology as Topic | 1 | 2009 | 141 | 0.330 |
Why?
|
| Cell Cycle Proteins | 2 | 2007 | 230 | 0.320 |
Why?
|
| Quality of Life | 3 | 2020 | 1515 | 0.320 |
Why?
|
| Cohort Studies | 12 | 2022 | 2356 | 0.310 |
Why?
|
| Injury Severity Score | 6 | 2018 | 204 | 0.310 |
Why?
|
| Prognosis | 6 | 2016 | 2093 | 0.310 |
Why?
|
| Gram-Negative Bacteria | 2 | 2005 | 55 | 0.310 |
Why?
|
| Sensitivity and Specificity | 7 | 2019 | 1753 | 0.300 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2007 | 27 | 0.300 |
Why?
|
| Hyperplasia | 1 | 2007 | 89 | 0.300 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 711 | 0.300 |
Why?
|
| Incidence | 5 | 2020 | 1582 | 0.300 |
Why?
|
| Mitosis | 1 | 2007 | 76 | 0.290 |
Why?
|
| Postoperative Complications | 6 | 2020 | 1615 | 0.290 |
Why?
|
| Hospital Costs | 1 | 2007 | 117 | 0.280 |
Why?
|
| Cardiomegaly | 1 | 2007 | 213 | 0.280 |
Why?
|
| Logistic Models | 6 | 2020 | 1419 | 0.270 |
Why?
|
| Cell Cycle | 1 | 2007 | 312 | 0.270 |
Why?
|
| Shock, Septic | 3 | 2020 | 101 | 0.270 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 328 | 0.260 |
Why?
|
| Cost of Illness | 1 | 2007 | 204 | 0.260 |
Why?
|
| Length of Stay | 6 | 2012 | 780 | 0.250 |
Why?
|
| Betacoronavirus | 3 | 2020 | 116 | 0.250 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 1851 | 0.250 |
Why?
|
| Young Adult | 9 | 2020 | 5708 | 0.250 |
Why?
|
| Washington | 3 | 2013 | 27 | 0.250 |
Why?
|
| Pilot Projects | 3 | 2019 | 1341 | 0.240 |
Why?
|
| Aged | 18 | 2018 | 14842 | 0.240 |
Why?
|
| Community Health Nursing | 1 | 2003 | 14 | 0.240 |
Why?
|
| Patient Isolation | 1 | 2003 | 35 | 0.230 |
Why?
|
| Cell Culture Techniques | 2 | 2005 | 189 | 0.230 |
Why?
|
| Pancreas | 2 | 2018 | 225 | 0.230 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 3256 | 0.230 |
Why?
|
| Drug Therapy | 1 | 2003 | 71 | 0.230 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2003 | 53 | 0.230 |
Why?
|
| Trauma Centers | 4 | 2013 | 197 | 0.220 |
Why?
|
| Fractures, Open | 1 | 2022 | 11 | 0.220 |
Why?
|
| Inflammation | 1 | 2009 | 1030 | 0.220 |
Why?
|
| Algorithms | 3 | 2017 | 1194 | 0.210 |
Why?
|
| Heart | 2 | 2007 | 850 | 0.210 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 88 | 0.200 |
Why?
|
| Peptic Ulcer | 1 | 2020 | 37 | 0.190 |
Why?
|
| Decontamination | 1 | 2020 | 11 | 0.190 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 25 | 0.190 |
Why?
|
| Hepacivirus | 3 | 2005 | 90 | 0.190 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2013 | 131 | 0.180 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 18 | 0.180 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 95 | 0.180 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 442 | 0.180 |
Why?
|
| Disinfectants | 1 | 2020 | 61 | 0.180 |
Why?
|
| Perioperative Care | 1 | 2020 | 100 | 0.170 |
Why?
|
| Melanoma | 1 | 2003 | 335 | 0.170 |
Why?
|
| United States | 6 | 2017 | 7335 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2003 | 375 | 0.170 |
Why?
|
| Medical Informatics | 1 | 2019 | 71 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 378 | 0.160 |
Why?
|
| Family | 1 | 2020 | 293 | 0.160 |
Why?
|
| Abdominal Injuries | 1 | 2018 | 60 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2020 | 311 | 0.160 |
Why?
|
| Program Evaluation | 1 | 2020 | 502 | 0.160 |
Why?
|
| Surgeons | 1 | 2019 | 68 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2019 | 159 | 0.160 |
Why?
|
| APACHE | 7 | 2016 | 41 | 0.160 |
Why?
|
| Acute Disease | 4 | 2022 | 658 | 0.150 |
Why?
|
| Communication | 1 | 2020 | 329 | 0.150 |
Why?
|
| Wound Healing | 1 | 2019 | 260 | 0.150 |
Why?
|
| Hospitalization | 4 | 2020 | 977 | 0.150 |
Why?
|
| Colorectal Surgery | 1 | 2017 | 11 | 0.150 |
Why?
|
| Health Personnel | 1 | 2020 | 286 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2021 | 413 | 0.150 |
Why?
|
| Shock | 1 | 2017 | 28 | 0.150 |
Why?
|
| Cytokines | 3 | 2014 | 866 | 0.150 |
Why?
|
| General Surgery | 2 | 2016 | 95 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 52 | 0.150 |
Why?
|
| ROC Curve | 2 | 2016 | 392 | 0.150 |
Why?
|
| Poverty | 1 | 2018 | 218 | 0.140 |
Why?
|
| Ethics, Institutional | 1 | 2016 | 3 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2017 | 2004 | 0.140 |
Why?
|
| Patient Rights | 1 | 2016 | 11 | 0.140 |
Why?
|
| Text Messaging | 1 | 2016 | 47 | 0.140 |
Why?
|
| Glutamine | 2 | 2006 | 45 | 0.140 |
Why?
|
| Hepatitis C | 3 | 2005 | 114 | 0.140 |
Why?
|
| Odds Ratio | 3 | 2017 | 880 | 0.140 |
Why?
|
| Confidentiality | 1 | 2016 | 62 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 109 | 0.130 |
Why?
|
| Survival Rate | 4 | 2013 | 1055 | 0.130 |
Why?
|
| Ethics, Medical | 1 | 2016 | 86 | 0.130 |
Why?
|
| Obesity | 2 | 2016 | 1074 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2013 | 242 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2022 | 62 | 0.130 |
Why?
|
| Time Factors | 8 | 2017 | 4655 | 0.130 |
Why?
|
| Morbidity | 2 | 2007 | 130 | 0.130 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 106 | 0.130 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2798 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 219 | 0.130 |
Why?
|
| Diabetes Complications | 1 | 2016 | 249 | 0.130 |
Why?
|
| Wounds, Penetrating | 2 | 2018 | 45 | 0.130 |
Why?
|
| Multivariate Analysis | 5 | 2013 | 1046 | 0.130 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2012 | 15 | 0.120 |
Why?
|
| Clothing | 1 | 2014 | 7 | 0.120 |
Why?
|
| Wheelchairs | 1 | 2014 | 16 | 0.120 |
Why?
|
| Sexuality | 1 | 2014 | 12 | 0.120 |
Why?
|
| Comorbidity | 4 | 2017 | 1425 | 0.120 |
Why?
|
| Bayes Theorem | 1 | 2016 | 303 | 0.120 |
Why?
|
| Cell Division | 2 | 2007 | 541 | 0.120 |
Why?
|
| Enteral Nutrition | 2 | 2006 | 157 | 0.120 |
Why?
|
| Skin Care | 1 | 2013 | 14 | 0.120 |
Why?
|
| Self Report | 1 | 2016 | 370 | 0.120 |
Why?
|
| Pseudomonas Infections | 2 | 2019 | 83 | 0.120 |
Why?
|
| Splenic Artery | 1 | 2013 | 16 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2019 | 133 | 0.120 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2012 | 226 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2015 | 652 | 0.120 |
Why?
|
| Information Storage and Retrieval | 1 | 2013 | 49 | 0.110 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 156 | 0.110 |
Why?
|
| Interviews as Topic | 1 | 2014 | 392 | 0.110 |
Why?
|
| Social Behavior | 1 | 2014 | 164 | 0.110 |
Why?
|
| Natural Language Processing | 1 | 2013 | 69 | 0.110 |
Why?
|
| Staphylococcus aureus | 2 | 2017 | 175 | 0.110 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 281 | 0.110 |
Why?
|
| Spleen | 1 | 2013 | 301 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2014 | 368 | 0.110 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2012 | 7 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 772 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 563 | 0.110 |
Why?
|
| Self Care | 1 | 2014 | 252 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2014 | 403 | 0.100 |
Why?
|
| Hospitals, University | 2 | 2014 | 169 | 0.100 |
Why?
|
| Linear Models | 2 | 2017 | 521 | 0.100 |
Why?
|
| Liver Transplantation | 2 | 2005 | 400 | 0.100 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 150 | 0.100 |
Why?
|
| Cause of Death | 1 | 2012 | 241 | 0.100 |
Why?
|
| Mortality | 1 | 2011 | 162 | 0.100 |
Why?
|
| Glasgow Coma Scale | 1 | 2010 | 65 | 0.100 |
Why?
|
| Pain | 1 | 2014 | 472 | 0.090 |
Why?
|
| Emergency Treatment | 1 | 2010 | 52 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2013 | 374 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2011 | 714 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2017 | 866 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 503 | 0.090 |
Why?
|
| Abdominal Cavity | 1 | 2009 | 3 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 546 | 0.090 |
Why?
|
| Liver | 2 | 2005 | 1118 | 0.090 |
Why?
|
| Bronchoscopy | 1 | 2010 | 147 | 0.090 |
Why?
|
| Tomography, Spiral Computed | 1 | 2009 | 57 | 0.080 |
Why?
|
| Oxazolidinones | 1 | 2008 | 6 | 0.080 |
Why?
|
| Acetamides | 1 | 2008 | 17 | 0.080 |
Why?
|
| Mycoses | 2 | 2009 | 60 | 0.080 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 45 | 0.080 |
Why?
|
| Vancomycin | 1 | 2008 | 60 | 0.080 |
Why?
|
| Enterococcus | 2 | 2008 | 29 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2005 | 230 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 83 | 0.080 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2007 | 3 | 0.080 |
Why?
|
| G2 Phase | 1 | 2007 | 26 | 0.080 |
Why?
|
| Viral Proteins | 2 | 2005 | 149 | 0.080 |
Why?
|
| Intracellular Space | 1 | 2007 | 42 | 0.080 |
Why?
|
| Virginia | 1 | 2007 | 45 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2007 | 89 | 0.070 |
Why?
|
| Protein Interaction Mapping | 1 | 2007 | 62 | 0.070 |
Why?
|
| Depression | 1 | 2014 | 942 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 159 | 0.070 |
Why?
|
| Estradiol | 1 | 2008 | 176 | 0.070 |
Why?
|
| Microscopy, Electron | 2 | 2005 | 351 | 0.070 |
Why?
|
| Microfilament Proteins | 1 | 2007 | 102 | 0.070 |
Why?
|
| Recurrence | 4 | 2015 | 948 | 0.070 |
Why?
|
| Genetic Variation | 2 | 2005 | 220 | 0.070 |
Why?
|
| Drug Costs | 1 | 2007 | 87 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 322 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 177 | 0.070 |
Why?
|
| Animals, Newborn | 1 | 2007 | 396 | 0.070 |
Why?
|
| DNA Replication | 1 | 2007 | 167 | 0.070 |
Why?
|
| Patient Admission | 1 | 2007 | 99 | 0.070 |
Why?
|
| Research Design | 2 | 2022 | 729 | 0.070 |
Why?
|
| Spheroids, Cellular | 1 | 2005 | 45 | 0.070 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2019 | 92 | 0.070 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2019 | 35 | 0.070 |
Why?
|
| Mice | 2 | 2007 | 8472 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 954 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2004 | 35 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 63 | 0.060 |
Why?
|
| Pancreatic Ducts | 2 | 2018 | 76 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 1039 | 0.060 |
Why?
|
| Animals | 3 | 2007 | 20877 | 0.060 |
Why?
|
| Viral Envelope Proteins | 1 | 2004 | 43 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 4843 | 0.060 |
Why?
|
| Hepatocytes | 1 | 2005 | 205 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2003 | 2 | 0.060 |
Why?
|
| Surgery Department, Hospital | 1 | 2003 | 19 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 1506 | 0.060 |
Why?
|
| Gentamicins | 1 | 2003 | 68 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 2003 | 53 | 0.060 |
Why?
|
| Blood Component Transfusion | 1 | 2003 | 11 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 166 | 0.060 |
Why?
|
| Actin Cytoskeleton | 1 | 2003 | 37 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2003 | 114 | 0.060 |
Why?
|
| Extremities | 1 | 2022 | 49 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2003 | 175 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 455 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2017 | 216 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2003 | 324 | 0.050 |
Why?
|
| Lithiasis | 1 | 2021 | 2 | 0.050 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 84 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2007 | 2673 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 127 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2022 | 149 | 0.050 |
Why?
|
| Fecal Impaction | 1 | 2020 | 2 | 0.050 |
Why?
|
| Sodium Hypochlorite | 1 | 2020 | 6 | 0.050 |
Why?
|
| Adolescent | 4 | 2017 | 8903 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 799 | 0.050 |
Why?
|
| Absenteeism | 1 | 2020 | 27 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 89 | 0.050 |
Why?
|
| Aerosols | 1 | 2020 | 42 | 0.050 |
Why?
|
| Health Facilities | 1 | 2020 | 35 | 0.050 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 2 | 0.050 |
Why?
|
| Enterococcus faecium | 1 | 2019 | 3 | 0.050 |
Why?
|
| Acinetobacter Infections | 1 | 2019 | 5 | 0.050 |
Why?
|
| Patient Care Bundles | 1 | 2019 | 5 | 0.050 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2019 | 6 | 0.050 |
Why?
|
| Klebsiella Infections | 1 | 2019 | 13 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 18 | 0.050 |
Why?
|
| Thiamine | 1 | 2019 | 11 | 0.050 |
Why?
|
| Methylene Blue | 1 | 2019 | 16 | 0.050 |
Why?
|
| Vitamin B Complex | 1 | 2019 | 25 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2019 | 45 | 0.050 |
Why?
|
| Organ Dysfunction Scores | 1 | 2019 | 13 | 0.050 |
Why?
|
| Lacerations | 1 | 2019 | 13 | 0.040 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2019 | 25 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2020 | 168 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2020 | 91 | 0.040 |
Why?
|
| Checklist | 1 | 2020 | 76 | 0.040 |
Why?
|
| Acinetobacter baumannii | 1 | 2019 | 22 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2019 | 17 | 0.040 |
Why?
|
| Surface Properties | 1 | 2020 | 363 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 107 | 0.040 |
Why?
|
| Netherlands | 1 | 2019 | 68 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 122 | 0.040 |
Why?
|
| Surgical Stapling | 1 | 2018 | 3 | 0.040 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2018 | 24 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1034 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2019 | 220 | 0.040 |
Why?
|
| Remote Consultation | 1 | 2019 | 50 | 0.040 |
Why?
|
| Sutures | 1 | 2018 | 32 | 0.040 |
Why?
|
| Pancreatic Fistula | 1 | 2018 | 23 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2003 | 738 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 438 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2020 | 237 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 592 | 0.040 |
Why?
|
| Patient Safety | 1 | 2020 | 202 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 2083 | 0.040 |
Why?
|
| Machine Learning | 1 | 2019 | 170 | 0.040 |
Why?
|
| Drainage | 1 | 2018 | 133 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 429 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2007 | 2688 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2018 | 129 | 0.040 |
Why?
|
| Antioxidants | 1 | 2019 | 304 | 0.040 |
Why?
|
| Streptococcus pyogenes | 1 | 2017 | 20 | 0.040 |
Why?
|
| Pregnancy | 1 | 2003 | 2331 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 116 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 38 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 659 | 0.040 |
Why?
|
| Tetraspanin 28 | 2 | 2005 | 4 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 410 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2015 | 13 | 0.030 |
Why?
|
| Patient Preference | 1 | 2016 | 57 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 277 | 0.030 |
Why?
|
| RNA, Viral | 2 | 2005 | 93 | 0.030 |
Why?
|
| Peritonitis | 1 | 2015 | 46 | 0.030 |
Why?
|
| Aftercare | 1 | 2016 | 114 | 0.030 |
Why?
|
| Rats | 1 | 2003 | 5300 | 0.030 |
Why?
|
| Fever | 1 | 2015 | 96 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2020 | 702 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2005 | 242 | 0.030 |
Why?
|
| 2-Propanol | 1 | 2013 | 4 | 0.030 |
Why?
|
| Povidone-Iodine | 1 | 2013 | 16 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 36 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 536 | 0.030 |
Why?
|
| Ethanol | 1 | 2020 | 892 | 0.030 |
Why?
|
| Narration | 1 | 2013 | 29 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 2013 | 46 | 0.030 |
Why?
|
| Splenectomy | 1 | 2013 | 40 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 170 | 0.030 |
Why?
|
| Internet | 1 | 2016 | 390 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2013 | 82 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 563 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 1082 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 442 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 1446 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 560 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2015 | 335 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 946 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1609 | 0.020 |
Why?
|
| Drug Resistance, Fungal | 1 | 2009 | 8 | 0.020 |
Why?
|
| Transplants | 1 | 2009 | 28 | 0.020 |
Why?
|
| Laparotomy | 1 | 2009 | 65 | 0.020 |
Why?
|
| Linezolid | 1 | 2008 | 7 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 334 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2323 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 411 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2008 | 108 | 0.020 |
Why?
|
| Hypothermia | 1 | 2007 | 37 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2008 | 205 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 136 | 0.020 |
Why?
|
| Hepatoblastoma | 1 | 2005 | 2 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2005 | 5 | 0.020 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 13 | 0.020 |
Why?
|
| Hepatitis C Antibodies | 1 | 2005 | 19 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2007 | 158 | 0.020 |
Why?
|
| Reperfusion | 1 | 2005 | 78 | 0.020 |
Why?
|
| Contrast Media | 1 | 2009 | 594 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 230 | 0.020 |
Why?
|
| Aspergillus | 1 | 2005 | 8 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 357 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2007 | 284 | 0.020 |
Why?
|
| Candida albicans | 1 | 2005 | 38 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 208 | 0.020 |
Why?
|
| RNA | 1 | 2005 | 171 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2004 | 71 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2004 | 86 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 56 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2004 | 20 | 0.020 |
Why?
|
| Blood Cells | 1 | 2004 | 27 | 0.020 |
Why?
|
| Hospital Units | 1 | 2004 | 21 | 0.020 |
Why?
|
| Liver Failure | 1 | 2004 | 27 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2004 | 101 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2005 | 523 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1465 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2004 | 70 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 710 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 144 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 539 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 244 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 248 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1174 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 737 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1745 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 370 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 626 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 334 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 693 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 1849 | 0.010 |
Why?
|